Reser D, Seifert B, Klein M, Dreizler T, Hasenclever P, Falk V, Starck C
Clinic of Cardiac and Vascular Surgery, University Hospital Zurich, Zurich, Switzerland.
Perfusion. 2012 Nov;27(6):530-4. doi: 10.1177/0267659112454558. Epub 2012 Aug 3.
Numerous cardiopulmonary bypass circuits with various coatings designed to reduce the inflammatory response and to provide better hemocompatibility are available. The aim of this study was to compare the effect of phosphorylcholine-coated, albumin-heparin-coated and synthetic polymer-coated perfusion tubing systems on patient outcome.
We performed a retrospective database review of elective patients between January 1st 2010 and December 31st 2010. Demographics, preoperative, operative, postoperative data and follow-up were collected and statistically analysed.
We identified 201 patients and formed three groups: Group 1 with phosphorylcholine coating (n=133), Group 2 with albumin-heparin coating (n=32) and Group 3 synthetic polymer coating (n=36). Mean age was 68 ± 11 years, additive Euroscore 5.8 ± 2.7. In-hospital outcomes were comparable between the groups without statistically significant differences. The overall 30-day and 1-year late survival were 98.5% and 96.7 ± 1.9%, respectively.
Our findings suggest that in-hospital and follow-up outcomes are comparable in cardiac surgery patients after using either phosphorylcholine-coated, albumin-heparin-coated or synthetic polymer-coated circuits during cardiopulmonary bypass.
目前有许多带有各种涂层的体外循环回路,这些涂层旨在减轻炎症反应并提供更好的血液相容性。本研究的目的是比较磷酸胆碱涂层、白蛋白-肝素涂层和合成聚合物涂层的灌注管路系统对患者预后的影响。
我们对2010年1月1日至2010年12月31日期间的择期手术患者进行了回顾性数据库审查。收集了人口统计学、术前、术中、术后数据以及随访情况,并进行了统计分析。
我们确定了201例患者,并将其分为三组:第1组为磷酸胆碱涂层组(n = 133),第2组为白蛋白-肝素涂层组(n = 32),第3组为合成聚合物涂层组(n = 36)。平均年龄为68±11岁,欧洲心脏手术风险评估系统(Euroscore)评分为5.8±2.7。各组的院内结局具有可比性,无统计学显著差异。30天总体生存率和1年远期生存率分别为98.5%和96.7±1.9%。
我们的研究结果表明,在体外循环期间使用磷酸胆碱涂层、白蛋白-肝素涂层或合成聚合物涂层的回路后,心脏手术患者的院内结局和随访结局具有可比性。